SPY415.21-2.05 -0.49%
DIA340.75-1.11 -0.32%
IXIC13,914.77-137.58 -0.98%

ImmunoPrecise Antibodies Highlights Results From Comprehensive Screening Of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA")

· 03/16/2021 07:31

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSXV:IPA) a leader in full-service, therapeutic antibody discovery and development, today has confirmed the results of an additional PolyTope™ antibody interaction analysis against SARS-CoV-2 spike protein variants of concern.

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants. Results of the screening also indicate that identified antibodies retain the ability to bind to emerging SARS-CoV-2 variants including U.K. (B.1.1.7 lineage), S. African (B.1.351 lineage) and Brazilian (P.1 lineage) strains.

Jennifer Bath, President and CEO commented, "While single and dual antibody therapies enabled a faster path to the clinic initially; these therapies do not directly address long-term protection against the virus's inevitable escape via its prolific ability to mutate — which we believe will ultimately be necessary to eradicate the threat of SARS-CoV-2 to human health."

Researchers studying SARS-CoV-2, the virus that causes COVID-19, have indicated that global variants are more transmissible than the original strain. As such, there has been an increasing focus in multi-antibody cocktail therapies. Currently, there are no multi-antibody therapies containing three or more antibodies in human clinical trials, despite the fact that a multi-antibody approach is widely believed to be the most promising path to containing SARS-CoV-2 variants.

The PolyTope platform developed by the Company has produced a diverse library of therapeutic antibody preclinical candidates which, when combined into a multi-antibody cocktail therapy, may assist in reaching the goal to effectively prevent mutational escape, unlock synergistic effects and improve efficacy and reduction in dosage requirements of future potential treatments.